Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Big pharma is set to keep signing bigger deals in 2024

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Oct 09, 2024 4:08pm

137 Views

Post# 36259929

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024

Correction that should read: Another factoid is that allogenic CAR-T therapy has been difficult to manufacture as "off-the-shelf" CAR-T products due to batch-to-batch variability which translates into difficulty of achieving of batch-to-batch reproducibility. Consequently personalized autologous CAR-T therapies remain the standard therapy.

<< Previous

Bullboard Posts

Next >>

The top 10 artificial intelligence penny stocks